Compare Ferrari NV (RACE) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs Revvity Inc — how do they compare? Ferrari NV trades at $388.62 (market cap $67.35B), while Revvity Inc trades at $155.03 (market cap $16.98B). The key difference: Ferrari NV is far larger — about 4× Revvity Inc's market cap, and Ferrari NV pays the higher dividend (1.09%). Which is the better fit depends on your goals — on Pluang, investors hold Ferrari NV for 126 Days and Revvity Inc for 12 Days on average.
| RACE | RVTY | |
|---|---|---|
Market Cap | $67.35B | $16.98B |
Volume | 390,618 | 1,456,900 |
Sector | Consumer Cyclical | Health |
52-Week High | $436.54 | $157.36 |
52-Week Low | $314.63 | $82.26 |
Typical Hold Time | 126 Days | 12 Days |
Enterprise Value | $69.22B | $19.30B |
Dividend Yield | 1.09% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $390.13, up 0.97% today, with a bearish technical signal but strong fundamentals including 22.25% net income margin and consistent earnings beats. Revenue grew to $7.15B in 2025, and the company is executing a share buyback program. Analyst consensus is bullish with a $462.75 price target, though technical indicators show resistance near $390.
The stock offers upside based on premium brand strength and profitability, but faces risks from high valuation multiples (P/E 37.19) and economic sensitivity. Institutional accumulation and positive media coverage support sentiment, yet investors should weigh technical resistance against fundamental growth prospects.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
